BioNTech shares are sliding after first-quarter 2026 results showed revenues of €118.1 million, down from €182.8 million a year earlier, and a net loss of €531.9 million. Investors are weighing higher R&D spending (€557.0 million) and a wider operating loss alongside a reaffirmed 2026 revenue outlook of €2.0–€2.3 billion and a new $1.0 billion ADS buyback plan.
1. What’s moving the stock
BioNTech (BNTX) is trading lower as the market digests its first-quarter 2026 financial update released May 5, 2026. The print highlighted a sharp year-over-year revenue decline and deep losses, keeping the focus on near-term earnings pressure while the company invests heavily to advance its oncology pipeline. (stocktitan.net)
2. The key numbers investors are reacting to
BioNTech reported Q1 2026 revenues of €118.1 million versus €182.8 million in Q1 2025, alongside a net loss of €531.9 million. R&D expenses rose to €557.0 million, underscoring the cost burden of running multiple late-stage programs in parallel. (stocktitan.net)
3. Guidance, cash, and shareholder actions
BioNTech reaffirmed its full-year 2026 revenue guidance range of €2.0 billion to €2.3 billion and reported cash, cash equivalents, and investments of €16.8 billion as of March 31, 2026. The company also authorized an ADS repurchase program of up to $1.0 billion over the next twelve months, but the stock reaction suggests investors are prioritizing the earnings trajectory over capital return in the near term. (stocktitan.net)
4. Pipeline progress vs. near-term profitability
Management highlighted progress across oncology, including initiating five additional pivotal trials for pumitamig in collaboration with Bristol Myers Squibb since the start of the year. Even with that momentum, the quarter’s lower revenue base and higher operating cost structure are driving the day’s downside move. (globenewswire.com)
BNTX•
